All lymph node biopsy samples were stained for CD19 (pan B-cell marker), CD20 (pan B-cell marker), CD138 (plasma cells), CD23 (follicular dendritic cells (FDCs)), PD-1 (follicular T helper cells, TFH) ...

T cells are white blood cells that are important for adaptive immunity. They have unique cell surface receptors that are generated by randomly assorting genes. These receptors allow T cells to ...

In accordance with the marker genes (Figure S6D), the cells were classified into clusters 1–9 corresponding to proximal convoluted tubule cells, proximal tubule cells, glomerular parietal endothelial ...

While NOTCH guides thymus progenitors toward T cell fate, the absence or disruption of NOTCH signaling renders the thymus microenvironment permissive to other cell fates. Following T cell commitment, ...

15 Lymphoma cells from a pleural effusion in a pediatric patient with T-cell lymphoblastic disease ... surface CD3 and TCRαβ (Figure 1). Markers associated to B (CD19), NK (CD16/56) or ...

However, whether the drug treatments directly or indirectly affect the Müller cells remains unclear. The purpose of these studies is to investigate how Sphingosine-1-phosphate (S1P) signaling ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

In proliferating cells the tetramer:dimer ratio of M2-PK ... In combination with established tumor markers, EDTA-plasma Tumor M2-PK is a useful tool in diagnosis and/or surveillance of ...

Feb. 4, 2025 — Research has shown that a potential new targeted therapy for childhood brain cancer is effective in infiltrating and killing tumor cells in preclinical models tested in mice.

The answer lies in a T cell's unique ability to defy aging. To study this phenomenon, the researchers made use of specific biomarkers known as epigenetic markers that accumulate over time.

Despite advances in conventional treatment modalities, patients with metastatic CRC often face limited options and poor outcomes. Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful ...